Healthcare & Life Sciences Funding
Capvizr tracks Healthcare & Life Sciences funding activity across newly funded companies, lead investors, hiring signals, and market narratives.
Top company Eli LillyLargest round $50 billion560 deals
Recent Healthcare & Life Sciences rounds
- Eli Lilly · $70 million · Series B · September 11, 2026
- Tempest Therapeutics · $7.5 million · Series A · September 11, 2026
- One Biosciences · an undisclosed amount · Series A · September 11, 2026
- Solstice Oncology · $225 million · Series A · September 10, 2026
- Encoded Therapeutics · $275 million · Series F · September 9, 2026
- A new immuno-oncology play · $225 million · Funding Round · September 9, 2026
- TwoStep Therapeutics · $62.5 million · Series A · September 9, 2026
- Ridge Bio · $38 million · Seed · September 9, 2026
- Allogenetics · an undisclosed amount · Pre-Series A · September 9, 2026
- Cloverleaf Bio · $33 million · Seed · September 8, 2026
Market context
Healthcare & Life Sciences deal flow is monitored for capital concentration, mega-rounds, and hiring expansion.
Open Healthcare & Life Sciences in the interactive Capvizr dashboard →